Patents by Inventor Erkan Karakas

Erkan Karakas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenylethanolamine-based NMDA receptor antagonists
    Patent number: 9382227
    Abstract: Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): wherein one or more of R1, R2, R3, R4, R5, or the ring formed by the joining of R1 and R2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing NMDA receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the GluN1/GluN2B NMDA receptor, particularly at the interface between GluN1 and GluN2B subunits. In silico methods are further described herein.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: July 5, 2016
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Hiro Furukawa, Erkan Karakas
  • PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS
    Publication number: 20140200244
    Abstract: Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): wherein one or more of R1, R2, R3, R4, R5, or the ring formed by the joining of R1 and R2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing NMDA receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the GluN1/GluN2B NMDA receptor, particularly at the interface between GluN1 and GluN2B subunits. In silico methods are further described herein.
    Type: Application
    Filed: January 2, 2014
    Publication date: July 17, 2014
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Hiro Furukawa, Erkan Karakas
  • Phenylethanolamine-based NMDA receptor antagonists
    Patent number: 8648198
    Abstract: Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): wherein one or more of R1, R2, R3, R4, R5, or the ring formed by the joining of R1 and R2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing NMDA receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the GluN1/GluN2B NMDA receptor, particularly at the interface between GluN1 and GluN2B subunits. In silico methods are further described herein.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: February 11, 2014
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Hiro Furukawa, Erkan Karakas
  • PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS
    Publication number: 20120294804
    Abstract: Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): wherein one or more of R1, R2, R3, R4, R5, or the ring formed by the joining of R1 and R2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing NMDA receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the GluN1/GluN2B NMDA receptor, particularly at the interface between GluN1 and GluN2B subunits. In silico methods are further described herein.
    Type: Application
    Filed: January 19, 2012
    Publication date: November 22, 2012
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Hiro Furukawa, Erkan Karakas